Sign in
Active, not recruitingPhase 2

The NOVA-NOA Trial A Novel Aromatase Inhibitor, Leflutrozole, for Treatment of Non-Obstructive Azoospermia

Key facts

Who runs it
Herlev Hospital
Where
Denmark1 site in 1 countryChoose a country to see its sites
Status
Active, not recruiting
Phase
Phase 2
People taking part
15 people, planned
Started
30 Jun 2026
Expected to end
15 Apr 2027
Type of study
Interventional
Record updated
14 October 2026

Who can take part

Age
18 years to 64 years
Sex
Men only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Signed informed consent by participant
  • Signed informed consent by participant’s partner (must just be obtained before the participant starts treatment at Visit 1), if applicable, regarding blood samples, data col-lection about fertility treatment as well as pregnancy and pregnancy outcome
  • 18-55 years
  • Azoospermia verified by at least 2 semen samples, average semen volume >= 1,0 ml with no identifiable sign of obstruction (samples taken at Visit -1 and at Visit 0 prior to confirmation of eligibility and dosing)
  • Serum AMH or Inhibin B level above the lower limit of quantification (LLOQ) at screening or within 6 months prior to screening
  • Testosterone < 15 nmol/L at screening or within 6 months prior to screening
  • Serum estradiol above the lower limit of normal range (48 pmol/L) at screening or within 6 months prior to screening

Who cannot take part

  • Use of any prescription or non-prescription medication (apart from routine vitamins, occasional use of paracetamol, acetylsalicylic acid, or ibuprofen) which could interfere with pharmacokinetic or pharmacodynamic results, as judged by the investigator, such as: o Herbal products and non-routine vitamins o Insulin o Medication such as systemic corticosteroids, tricyclic antidepressants, and atypical antipsychotics
  • Surgery scheduled for the trial duration period, except for minor, non-gastrointestinal surgical procedures at the discretion of the investigator
  • Hematocrit >50% at screening or within 6 months prior to screening
  • Current abuse of steroids
  • Prior thromboembolic event within the last 24 months
  • Klinefelter or other major genetic conditions including large deletions on sex chromo-somes
  • Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator’s opinion could interfere with the results of the trial
  • Severe chronic diseases requiring daily medication
  • Serum prostate specific antigen (PSA) > 3 ng/mL at screening or within 6 months prior to screening
  • Osteoporosis requiring medical treatment
  • Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator
  • Average testis size > 20 mL unless obstruction has been excluded
  • TESE procedure < ½ year ago
  • LH concentration > 15 IU/L at screening
  • BMI > 45 kg/m2
  • Cardiovascular event within the last 6 months judged as significant by the investigator

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this intervention is to investigate whether the aromatase inhibitor, Leflutrozole, can improve semen quality in a subgroup of infertile men

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Record updated
14 October 2026